Improve Research Reproducibility A Bio-protocol resource
Concise Method
tooltip

Sample size

CW Corinne Willame
DR Dominique Rosillon
JZ Julia Zima
MA Maria-Genalin Angelo
AS Anke L. Stuurman
HV Hilde Vroling
RB Rachael Boggon
EB Eveline M. Bunge
MP Manel Pladevall-Vila
LB Laurence Baril
ask Ask a question
Favorite

For the cohort design, by hypothesizing that the incidence rates of neuro-inflammatory AD vary between 1 and 10/100,000 person-years and the incidence rates of other AD vary between 50 and 100/100,000 person-years, cohorts of 50,000 subjects each should allow the detection, with 80% power, of a relative risk between 18.7 and 3.7 and between 2.0 and 1.6 respectively for the neuro-inflammatory AD and other AD (our 2 co-primary endpoints). Because of risk of loss to follow-up and missing data, the sample size was increased by 30% for a total of 65,000 subjects in each cohort.

Copyright and License information:  ©2016 Published with license by Taylor & Francis
This is an Open Access article distributed under the terms of the Creative Commons Attribution License http://creativecommons.org/licenses/by/3.0/, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted.

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

post Post a Question
0 Q&A